Seth Augenstein

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.

The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.